Linda Dear: Menodoctor Clinical Director on Pharmac's new measures to address HRT patch shortage

Heather du Plessis-Allan Drive

NZME and Newstalk ZB에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 NZME and Newstalk ZB 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

19h ago 2:05

MP3•에피소드 홈

Increased restrictions for HRT menopause treatment, as Pharmac finds ways shore up supply of oestradiol patches.

It's changing its main funded brand to Estradiol TDP Mylan from supplier Viatris from next July.

In order to ensure supply, it'll be the only funded brand available by December 2025.

Menodoctor Clinical Director, Linda Dear, says those who can't use the Mylan brand will have other options.

"Most women who get on with other, non-Mylan brands will get on with gel fine - but it means they'll have to start probably thinking about that transition."

LISTEN ABOVE

See omnystudio.com/listener for privacy information.

7926 에피소드

#News #NZME #Newstalk ZB